Vivus rises on Avanafil study

Avanafil was compared to placebo in a study of 284 men with erectile dysfunction (ED). The most significant results were produced when the drug was administered at a 300mg dose. 84% of men given this amount of the drug succeeded in having an erection capable of vaginal penetration, with 64% maintaining the erection sufficiently long enough for full intercourse.

During this multi-center study patients were instructed to attempt sexual intercourse 30 minutes after taking Avanafil, with no restrictions on food or alcohol consumption. A separate comparison group were given placebo and provided with the same instructions. Avanafil was well tolerated and no serious adverse events were reported.

The investigational oral phosphodiesterase type 5 (PDE5) inhibitor, Avanafil, is designed to be a fast-acting alternative to drugs such as Viagra produced by Pfizer. Viagra is also a PDE5 meaning it boosts blood-flow to the penis.

“Previous studies have suggested that Avanafil can potentially be taken twice a day for those patients that desire sexual intercourse more frequently than once per day, while maintaining the advantage of being rapidly removed from the body, thus reducing the duration of any side effects and the potential for interaction with drugs such as nitrates,” commented Dr John Dietrich, vice president of R&D at Vivus.